Perfuze Secures FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Comprehensive Stroke Thrombectomy System

Perfuze Receives FDA 510(k) Clearance for NeuroSheath, Completing Its Comprehensive Stroke Thrombectomy System Perfuze, a neurovascular medical device company focused on developing technologies for the treatment of stroke, has announced…

Read MorePerfuze Secures FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Comprehensive Stroke Thrombectomy System

Pattern Bioscience Begins Early Evaluation of Its Pneumonia ID/AST Panel at Five U.S. Clinical Laboratories

Pattern Bioscience Advances Pneumonia ID/AST Panel Evaluation Across Five U.S. Clinical Microbiology Laboratories Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, has announced that its Pneumonia ID/AST…

Read MorePattern Bioscience Begins Early Evaluation of Its Pneumonia ID/AST Panel at Five U.S. Clinical Laboratories

Aphena Pharma Solutions Implements QAD Adaptive ERP, Establishing a Modern Foundation for Enterprise Operations

Aphena Pharma Solutions Goes Live on QAD Adaptive ERP, Modernizing Pharmaceutical Manufacturing and Business Operations Aphena Pharma Solutions, a leading U.S.-based pharmaceutical contract manufacturing and packaging organization, has successfully gone…

Read MoreAphena Pharma Solutions Implements QAD Adaptive ERP, Establishing a Modern Foundation for Enterprise Operations

Povofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Incyte Receives European Commission Approval for Povofortay as a Once-Daily Oral Treatment for Moderate to Severe Hidradenitis Suppurativa Incyte has announced that the European Commission (EC) has approved Povofortay® (povorcitinib)…

Read MorePovofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Gilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Gilead Sciences Signs Royalty-Free Licensing Agreements to Support Potential Future Access to Investigational Obeldesivir for Ebola Prevention Gilead Sciences, has announced royalty-free voluntary licensing agreements with three generic pharmaceutical manufacturers…

Read MoreGilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement